Advertisement

Topics

Northern Biologics Announces CEO Transition

10:00 EST 9 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Philip Vickers named CEO Stefan Larson to rejoin Versant as a Venture Partner Northern Biologics Inc., a developer of first-in-class immuno-oncology products, today announced that Philip Vickers, Ph.D., is joining t...

Other Sources for this Article

Versant Ventures
Steve Edelson, 415-801-8088
sedelson@versantventures.com

NEXT ARTICLE

More From BioPortfolio on "Northern Biologics Announces CEO Transition"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...